[rxsid]

Some noteworthy articles in the news about RLF-100...

RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells (August 2, 2020)

• - Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites

• - Aviptadil is being developed as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes

• - RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide VIP), which has been granted FDA Fast Track Designation, FDA emergency use IND authorization, and an expanded access protocol

RADNOR, Pa. and GENEVA, Aug. 2, 2020 /PRNewswire/ -- NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) "Relief" today announced that RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19. At the same time, independent researchers have reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes.

RLF-100 has been granted Fast Track designation by FDA and is being developed as a Material Threat Medical Countermeasure in cooperation with the National Institutes of Health and other federal agencies. Further research will be conducted.

The first report of rapid clinical recovery under emergency use IND was posted by doctors from Houston Methodist Hospital. The report describes a 54-year-old man who developed COVID-19 while being treated for rejection of a double lung transplant and who came off a ventilator within four days.1 Similar results were subsequently seen in more than 15 patients treated under emergency use IND and an FDA expanded access protocol which is open to patients too ill to be admitted to the ongoing Phase 2/3 FDA trial.

Patients with Critical COVID-19 were seen to have a rapid clearing of classic pneumonitis findings on x-ray, accompanied by an improvement in blood oxygen and a 50% or greater average decrease in laboratory markers associated with COVID-19 inflammation.2

The clinical findings may be based on evidence that VIP inhibits the replication of the SARS-CoV-2 virus in human lung cells and immune cells (monocytes). The work was reported by Brazilian researchers working in a level-4 biocontainment laboratory.3 The same researchers reported a case-control study in which patients who survived being on ventilators for COVID-19 had significantly higher levels of VIP in their blood than those who died of respiratory failure.

"No other antiviral agent has demonstrated rapid recovery from viral infection and demonstrated laboratory inhibition of viral replication," said Prof. Jonathan Javitt, CEO and Chairman of NeuroRx. "We are conducting placebo-controlled trials to see whether the observations made in the case-control and open-label studies will be confirmed for less ill patients with COVID-19-related respiratory failure. Our independent Data Monitoring Committee will be conducting an interim analysis of these data later this month."

Others...

Rapid Recovery from COVID-19 Respiratory Failure after treatment with Vasoactive Intestinal Peptide

Relief, NeuroRx say emergency treatment with RLF-100 helps critically ill Covid patients [2]

Critically ill COVID-19 patients make quick recovery with treatment RLF-100

[rxsid]

This therapeutic looks promising for those that are most sick. This could be a perfect compliment to HCQ.

HCQ for prophylaxes and early disease stage, and Aviptadil for late disease stage.

[rxsid]

Ping!

The promising COVID therapy for respiratory failure few have heard of, but will soon - NeuroRx and Relief Therapeutics RLF-100 (Aviptadil)

[Presbyterian Reporter]

A big contributor to ACT BLUE-—

ontributor information
Name EDISON, PAMELA
City and state CHEVY CHASE, MD, 20815
Occupation DRUG DEVELOPMENT
Employer NEURORX
Year to date $183.34
Contribution information
Amount $166.67
Receipt date October 2, 2018
Report year 2018
Memo EARMARKED FOR CASTEN FOR CONGRESS (C00648493)
Reported on Form 3X on line 11AI
Election type
Recipient information
Committee ACTBLUE
Political party
Type PAC with Non-Contribution Account - Qualified
State Massachusetts

[enumerated]

Best kept secret:

The actual treatment protocol for those testing positive for Covid19?

Nothing. Nada. Zip. Zero.

You get sent home and told to rest. Stay away from other people if you have symptoms. Maybe take a Tylenol to reduce any fever. Wait for it to go away on its own. That’s it.

Unless, that is, you are sick from something else. In which case, the treatment varies according to whatever other conditions you are suffering from.

Except in rare cases, Covid19 is not what is killing people - even those who happen to be infected with it when they die.

How rare is it to die with Covid19 as the primary cause? We simply can’t know, because there has been no attempt to gather data in a way that would allow that crucial statistic to be reported.

The CDC and Big Pharma doesn’t want people to know the true morbidity of Covid19, because it would be far, far less alarming than the all-inclusive morbidity number being reported.

The truth is that they want us to be alarmed, so we will comply with their guidelines. So we will line up for their mandatory $$$ vaccine when the time comes. These bureaucrats posing as scientists are just power-happy Statists who never met a government program or regulation they didn’t like. They never met a crisis they couldn’t profit from.

If they have their way, they would be dictating every aspect of our lives - a pandemic fear - a climate change fear - a gun violence fear - it doesn’t matter. Fear is just a means of justifying control. Tyrants always use fear to get people to trade away their liberties, and Covid is no different. They want us all obediently sucking on the government test and lining up for vaccines and chip implants.

If the true risk of death from Covid was known, everyone would have chucked their masks and gone back to work a long time ago.

[cmj328]

We’ll only hear about it if it provides money for well-connected people.

[LucyT]

.

PING

Check out Article and # 1, # 2.

Thanks, rxsid.

[null and void]

Bring Out Your Dead

Post to me or FReep mail to be on/off the Bring Out Your Dead ping list.

The purpose of the “Bring Out Your Dead” ping list (formerly the “Ebola” ping list) is very early warning of emerging pandemics, as such it has a high false positive rate.

The false positive rate was 100%.

At some point we may well have a high mortality pandemic, and likely as not the “Bring Out Your Dead” threads will miss the beginning entirely.

*sigh* Such is life, and death...

If a quarantine saves just one child's or one old fart’s life, it's worth it.

[musicman]

BTTT!!!

[WildHighlander57]

Bookmarking!!

[rxsid]

UPDATE:

FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure

• - Aviptadil is now shown as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung
• - RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide, VIP), which has been granted FDA Fast Track Designation, FDA emergency use IND authorization, and an expanded access protocol

RADNOR, Pa. and GENEVA, Aug. 6, 2020 /PRNewswire/ -- NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) "Relief" today announced that NeuroRx has been granted Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 in order to prevent progression to respiratory failure.

The study is posted at https://clinicaltrials.gov/ct2/show/NCT04360096. The first phase will commence with patients hospitalized for severe COVID-19 who do not yet have respiratory failure. If promising results are seen in the inpatient setting, the trial will expand to patients at home with mild and moderate COVID-19 in order to prevent the need for hospital admission.

Professor Jonathan Javitt, MD, MPH, CEO of NeuroRx said, "Now that we know VIP suppresses replication of the SARS-CoV-2 virus in human lung cells, based on the outstanding work of the Oswaldo Cruz Institute (Rio de Janeiro),1 we are optimistic that treatment with VIP will not only help patients on ventilators, but will help to stop the advancement of the virus in patients with earlier stages of COVID-19. By blocking cytokine synthesis in the lung cells and increasing the production of surfactant, which is key to the lung's ability to transmit oxygen, we are hopeful that inhaled VIP will prove to be of clinical benefit across a wider array of patients suffering respiratory complications from COVID-19 infection."

The clinical trial of the inhaled formulation of RLF-100 is expected to begin on or before September 1, 2020.

https://www.prnewswire.com/news-releases/fda-grants-inhaled-use-ind-for-rlf-100-aviptadil-to-treat-patients-with-moderate-and-severe-covid-19-aiming-to-prevent-progression-to-respiratory-failure-301107288.html

[rxsid]

The CEO of Relief Therapeutics, Dr. Raghuram Selvarju was on Fox Business earlier today regarding RLF-100 (Aviptadil):

Doctor hopeful inhaled version of drug can combat early-stage coronavirus

Note: The injectable form of RLF-100 is for Wuhan-19 patients who are in serious/critical condition to prevent respiratory failure...while the inhaled version is for earlier/mid disease stage.

Yes, I know, Cavuto is anti HCQ and at least a bit of an anti-Trumper.

[rxsid]

This is great news https://t.co/IQhjoL4mzT— Dr Drew (@drdrew) August 12, 2020

The video interview: Discussion with Dr. Jonathan Javitt about Aviptadil and Vasoactive Intestinal Peptide

[rxsid]

Dr Oz. mentioned Aviptadil on Fox News last March:

https://www.youtube.com/watch?v=vQ_mrOkZnbc&feature=youtu.be&t=385

[rxsid]

Story of Houston Fire Capt Tommy Searcy.

Two others from Houston Fire have died of Covid 19,

Third Houston firefighter in ICU with COVID-19 as department prepares for another's funeral, union president reports

Capt Searcy is in critical, worsening condition as of this morning when RLF-100 was rushed to the hospital where he in on a ventilator.

After late night approvals from docs at @memorialhermann and execs at @NeuroRxPharma, @FirefightersHOU raced experimental COVID medication RLF-100 to ailing @HoustonFire Capt Tommy Searcy under escort early this morning. 'Now, we pray,' union leader tells @abc13houston pic.twitter.com/wpvXUAyVMw— Ted Oberg (@TedABC13) August 18, 2020

His brother Tommy, also a Houston firefighter, rushed the compassionate use pick up of RLF-100 to the hospital with police escort.

https://www.facebook.com/tony.searcy.7/videos/10219524769290019/

Now that Aviptadil has gained more attention, this case will be one to watch in the coming days. If he is able to recover from such a grave condition, after being administered Aviptadil, expect to hear much more on this promising therapeutic.

[JerseyDvl]

The powers that be do not want anything released that will actually help people... Until 11/4.

[rxsid]

Update on the testing going on at Houston Methodist Hospital (site) / Johns Hopkins University (contributor)

This is a "preprint" of the to-be officially released report on that study in Texas. Very, very encouraging:

Rapid Recovery from COVID-19 Respiratory Failure with comorbidity in 21 patients treated with Vasoactive Intestinal Peptide

Background: Vasoactive Intestinal Peptide (VIP) is known to bind to and protect Alveolar Type II cells by blocking replication of the SARS-CoV-2 virus, inhibiting cytokine synthesis, preventing cytopathy, and upregulating surfactant production. RLF-100 (Aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP) has been granted Fast Track Designation for treating Critical COVID-19 with Respiratory Failure and is currently in phase 2/3 placebo-controlled trials. FDA has granted Emergency Use IND and Expanded Access Protocol approval for the use of RLF-100 in patients whose comorbidities render them ineligible for inclusion in the ongoing pivotal trial.

...

Results: Median patient follow-up time is 21 days. So far, 19 of 21 patients have survived. One death was due to COVID-related multisystem organ failure and the other to an underlying and unrelated encephalopathy. Improved radiographic appearance of typical “ground glass” COVID-19 features to varying degrees is seen in both lungs of 17 patients and in one lung of 2 patients.. A mean 292% increase in PaO2:FiO2 ratio was seen during the time patients were on ventilation. Improvement in blood oxygenation is seen in all patients, with complete remission from respiratory failure in 9 patients and ongoing improvement in 10. Seven patients were discharged from the hospital, 7 have been sent to intermediate acute care, and 5 require ongoing intensive care. Three of 5 patients on extracorporeal membrane oxygenation (ECMO) prior to treatment with VIP have been decannulated and two have been discharged to home. A 75% (95% CI±3%: P<.001) reduction in IL-6 was seen with corresponding decrease in C-reactive protein. A median 4 point reduction in the NIAID Ordinal Scale was observed (P<.01).

...

Radiographic evidence (figure 2) on all patients is included in the online supplementary material. In all cases, clearing of the “ground glass” parenchymal changes associated with COVID-19 pneumonitis was apparent and was noted by the radiologists who read the chest x-rays. Quantitative analysis of radiographic changes will be the subject of a future report

https://t.co/hR3vi4RLB9?amp=1

[rxsid]

Looks like it's more and more likely that COVID-19 is indeed a "RANTES" disease. Some info...

Role of CCL5 (RANTES) in Viral Lung Disease (2006)
RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted), Inflammation, Obesity, and the Metabolic Syndrome (2007)

RANTES explained by Dr. Yo (Ram Yogendra M.D., M.P.H.) in YouTube vid - COVID-19 Update USA : How RANTES Can Explain Coronavirus Symptoms

[rxsid]

Aviptadil getting more traction...

New drug being used for COVID-19 patients with respiratory failure

"Dr. Sohail Rao, the president of the DHR Health Institute for Research & Development, announced Tuesday that DHR will be using Aviptadil to help patients fight the virus."

Watch the video for full story.

https://www.krgv.com/news/new-drug-being-used-for-covid-19-patients-with-respiratory-failure/

DHR Health Institute for Research & Development is out of Edinburg, TX.

[musicman]

BTTT!!!

[rxsid]

Aviptadil (RLF-100) For COVID-19: 21 Patients With Severe Refractory COVID Showing Improvements!
https://www.youtube.com/watch?v=QFAZjwxYZwo

Great presentation of the latest study, by Dr. "Whiteboard."

 

Note: He also did a whiteboard presentation back in July regarding HCQ+Zn+Azith:

Triple Therapy Zn, HCQ, And Azithro: NEW STUDY Using Triple Therapy For Outpatient Early COVID-19!
https://www.youtube.com/watch?v=4eR0oV0Yqwo